18 results about "Immune effects" patented technology

Provided are an RNA vaccine and a related product thereof, relating to the field of biomedicine. The RNA vaccine is a therapeutic vaccine. An antigen contained in the RNA vaccine comprises a combination of HPV16E6721 and HPV18E6721 or a combination of HPV16E672, HPV18E672 and HPV16 / 18E1. Compared with existing vaccines, the provided vaccine can induce viral clearance during a low-copy replication phase of the virus, and has a better immune effect.

The application discloses a phosphoric acid modified protein or polypeptide, a preparation method thereof and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide is as follows: a compound containing an aldehyde group and a phosphate group is subjected to nucleophilic reaction with a protein or polypeptide to form a Schiff base; a reducing agent is used to reduce the Schiff base, and after post-treatment, the phosphoric acid modified protein or polypeptide is obtained. After the phosphoric acid modified protein product prepared by the method is prepared into a vaccine with an aluminum hydroxide adjuvant and mice are immunized, the antibody titer is significantly increased. This is of great significance for increasing the immune effect, reducing the inoculation dose, saving the antigen amount and improving the immune response of some people or in specific conditions.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The application discloses a kind of for HBV PreS1 antibody qualitative detection test strip and its preparation method and application, it is related to virology, immunology, biological detection technology and immunochromatography analysis technical field.The test strip is based on the specific recognition principle of antigen and antibody, the specific binding of PreS1 antigen and PreS1 antibody is realized, the rapid detection of PreS1 antibody in serum or plasma sample, it is sequentially assembled by sample pad, gold mark pad, nitrocellulose membrane (NC membrane) and water absorption pad, wherein, gold mark pad is fixed with colloidal gold labeled anti-human IgG antibody as gold mark probe, NC membrane detection line (T line) is coated HBV PreS1 antigen, for capturing PreS1 antibody in sample, NC membrane quality control line (C line) is coated HB2 antibody, for judging whether the test strip detection process is effective.The test strip in the application does not need complex instrument equipment, detection process is simple, fast and fast, and has good sensitivity and specificity, can be used for hepatitis B vaccine immune effect evaluation and large-scale screening.

The application discloses a kind of nucleic acid nano vesicles based on sulfonium copolymerization peptide and its preparation method and application.The vesicle is formed by the electrostatic self-assembly of a kind of sulfonium copolymerization peptide and polynucleotide, and is stable nano vesicle with hollow structure.The vesicle is different from conventional solid nanoparticles, and its unique hollow structure provides space for co-loading other therapeutic agents (such as enzymes, chemotherapeutic drugs).The application also provides a preparation method of the nano vesicle, and its application as a carrier for simultaneously loading nucleic acid drugs and other active ingredients for synergistic treatment.The nano vesicle has extraordinary long-term storage stability, and can deliver siRNA and catalase to tumor sites, block CD47 "don't eat me" signal through gene silencing, and enzymatically degrade immunosuppressive factor H2O2 in tumor microenvironment, thereby remodeling tumor immune microenvironment, efficiently activating macrophages, dendritic cells and T cells, and producing strong synergistic anti-tumor immune effect.

The present application relates to a kind of nucleotide, vaccine comprising it and composite vaccine adjuvant.The sequence of the nucleotide is shown as SEQ ID No:1.Relative to conventional technology, the beneficial effects of the present application include: the present application adopts new optimized sequence, provides a kind of nucleotide, the nucleotide can be as CpG oligonucleotide adjuvant, induces vaccine antigen to produce stronger humoral immunity, cellular immunity level and anti-tumor immune effect etc., has obvious clinical application value and vaccine development value.Moreover, using the immunoadjuvant of the present application helps to reduce the dose of clinical use vaccine, improves safety.

This invention discloses a drug extract for enhancing the efficacy of porcine reproductive and respiratory syndrome (PRRS) vaccines, its preparation method, and its application. The drug extract comprises aqueous extracts of Astragalus membranaceus and Curcuma zedoaria, wherein the optimal mass ratio of Astragalus membranaceus to Curcuma zedoaria is 4-5:1. The Astragalus membranaceus and Curcuma zedoaria extract of this invention enhances the efficacy of existing PRRSV vaccines, improves vaccine resistance to PRRSV, and effectively stimulates the body to produce sufficient neutralizing antibodies, thereby enhancing the overall immune effect of the vaccine, with significantly better results than using the vaccine alone.

The application provides a mycoplasma gallisepticum triple subunit vaccine and application thereof, and the vaccine comprises EF-TU protein with an amino acid sequence as shown in SEQ ID NO. 1, PdHD protein with an amino acid sequence as shown in SEQ ID NO. 2, MS1360 protein with an amino acid sequence as shown in SEQ ID NO. 3 and a pharmaceutically acceptable adjuvant. The application realizes antigen epitope complementation and immune synergistic enhancement by screening the optimal vaccine formula through two-by-two mixed combination and three-protein concentration gradient mixed system screening of EF-TU, PdHD and MS1360 three high immunogenic membrane proteins, and solves the problems of low protection rate and unstable immune effect of the existing vaccine.

This invention discloses a bivalent subunit vaccine against Candida albicans, its preparation method, and its application, relating to the field of biomedical technology. The bivalent subunit vaccine comprises recombinant Als3 protein and recombinant Cht3 protein as immunogens. The recombinant Als3 protein is obtained based on the sequence shown in SEQ ID NO:1, through site-directed mutagenesis of the N-glycosylation site and weak epitopes LDGTSASPG and IVIVATTRT. The recombinant Cht3 protein is obtained based on the sequence shown in SEQ ID NO:2, through site-directed mutagenesis of the weak epitopes TTSVTSSET and YTANGILQC to enhance immunogenicity. This invention overcomes the bottleneck of prokaryotic expression of Cht3 antigen through a combination strategy of antigen extraction, expression strain optimization, mild induction, and multiple site-directed mutagenesis, obtaining a high-purity, highly immunogenic antigen. Furthermore, the bivalent combination of Als3 and Cht3 produces a synergistic immune effect, significantly improving the protective effect against Candida albicans infection. Simultaneously, the process is simple and easy for industrial production.

Recombinant BCG, a preparation method therefor and an application thereof. A shuttle plasmid that can express a FimH protein on the surface of BCG is constructed, and a gene fragment that expresses the FimH protein is transformed into wild-type BCG to thereby obtain recombinant BCG. Upon verification, the recombinant BCG can express the FimH protein on the surface of BCG; therefore, the BCG can specifically bind to subjects that can selectively bind to the FimH protein. The recombinant BCG can also enhance the local innate immune effect and adaptive immune effect induced by BCG and the anti-tumor effect of peripheral blood mononuclear cells, and also significantly improves the effect of BCG against bladder tumors, and is used to treat bladder tumors.

This invention relates to a novel fusion protein, immunogenic composition, recombinant vaccine, molecular architecture design, and applications for the prevention and treatment of Mycoplasma pneumoniae infection. The invention provides a novel fusion molecular architecture comprising fusion proteins encoded by the PstS and P37 genes, which can be used in the development of nucleic acid vaccines. The invention reveals that the novel fusion protein exhibits excellent immunogenicity, providing effective immune protection, significantly inhibiting Mycoplasma pneumoniae colonization, and, compared to nucleic acid vaccines encoding the P1-P30 fusion protein, which are known in the art to have excellent efficacy, demonstrates a more significant immune effect and protective effect against Mycoplasma pneumoniae infection, showing broad application prospects.

The application belongs to the technical field of biological medicine, and discloses application of ERBB4 as a treatment target in neuroblastoma treatment. The application discloses application of a reagent for detecting ERBB4 in preparation of a product for evaluating treatment efficacy of neuroblastoma. The application proves that ERBB4 is a potential risk factor for high-risk neuroblastoma recurrence through multi-omics research and mechanism analysis of metabolic regulation network of ERBB4, and verifies the preclinical application value of the target point through a verification test, thereby providing a new target point with stable expression for precise diagnosis and treatment of refractory and recurrent neuroblastoma. Experiments prove that high expression of ERBB4 plays an inhibitory role on neuroblastoma by activating immune effect, improves the response rate of neuroblastoma to chemotherapy and immunotherapy, improves the overall treatment efficiency, has good clinical transformation value, and has important significance for the treatment of neuroblastoma.

The present invention relates to the field of biomedicine, and specifically relates to drug development targeting SLC45A2 and application in immunotherapy. In the present invention, SLC45A2 on the surface of T cells is used as a target for immunotherapy. By regulating the SLC45A2 gene or an expression product thereof, the acid-base environment balance of the T cells is regulated and controlled, the ability of the T cells to secrete cytotoxic cytokines is regulated, and the exhaustion process of the T cells is controlled, thereby achieving the regulation and control of the immune function of the T cells. Based on this, in the present invention, a borate bioactive material targeting SLC45A2 is further developed. The material can significantly reduce the expression of SLC45A2, enhance the anti-tumor immune effect of the T cells, and exhibit significant anti-tumor effects both in vivo and in vitro.

The application discloses an adjuvant influenza vaccine and application, and relates to the technical field of biological vaccines.The adjuvant influenza vaccine comprises a CpG adjuvant, the CpG adjuvant is at least one selected from CpG HP007, CpG PV001, CpG 7909 and CpG 1018, and further comprises an aluminum adjuvant.The adjuvant influenza vaccine provided by the application can improve the antibody level by several times compared with traditional vaccines, can induce higher humoral immune response and cellular immune response, can effectively reduce the antigen usage, and can significantly improve the immune effect of the influenza vaccine on healthy people.

The application discloses a high-affinity mouse anti-Eudontomyzon vlk monoclonal antibody, a hybridoma cell line and application, the mouse anti-Eudontomyzon vlk monoclonal antibody can be obtained by secretion of hybridoma cell line (Hybridoma cell line) ArIgML-14D3C4D11F7, and the preservation number is CCTCC NO: C202544.The mouse anti-Eudontomyzon vlk monoclonal antibody provided by the application can be used for flow cytometry to identify IgK + B cells in eudontomyzon serum and spleen and the like, and can be used for ELISA and Western blot specific detection of eudontomyzon secreted IgK.The monoclonal antibody is specific, high in sensitivity and high in affinity, can be used for structure analysis of eudontomyzon IgK, immune response level detection and the like, lays a foundation for in-depth research of eudontomyzon immune system and establishment of a vaccine immune effect evaluation method taking an antibody level as an index.

The present application relates to a kind of human bocavirus broad-spectrum recombinant antigen, detection test paper and its preparation and application, to solve the technical problem of lack of simultaneous detection of multiple HBoV genotype antibody fast, simple diagnostic tool in prior art.The core of technical solution is: based on the design of broad-spectrum recombinant antigen (rVP1) of multiple types of common conserved epitope, and it is applied to the construction of colloidal gold immunochromatography test paper.The test paper will be marked in colloidal gold particles as detection probe, by indirect method reaction principle, can realize the synchronous detection of the antibody produced by four main genotypes of HBoV infection in 15-20 minutes.This scheme has the advantages of simple operation, without professional equipment, result is interpreted intuitively, while having good broad-spectrum, sensitivity and specificity, suitable for primary medical institutions rapid screening, field epidemiological investigation and vaccine immune effect evaluation and a variety of application scenarios.